Synthesis and tyrosine kinase inhibitory activity of a series of 2-amino-8H-pyrido[2,3-d]pyrimidines:: Identification of potent, selective platelet-derived growth factor receptor tyrosine kinase inhibitors

被引:90
|
作者
Boschelli, DH
Wu, ZP
Klutchko, SR
Showalter, HDH
Hamby, JM
Lu, GH
Major, TC
Dahring, TK
Batley, B
Panek, RL
Keiser, J
Hartl, BG
Kraker, AJ
Klohs, WD
Roberts, BJ
Patmore, S
Elliott, WL
Steinkampf, R
Bradford, LA
Hallak, H
Doherty, AM
机构
[1] Parke Davis Pharmaceut Res, Dept Med Chem, Ann Arbor, MI 48105 USA
[2] Parke Davis Pharmaceut Res, Dept Canc Res, Ann Arbor, MI 48105 USA
[3] Parke Davis Pharmaceut Res, Dept Vasc & Cardiac Dis, Ann Arbor, MI 48105 USA
[4] Parke Davis Pharmaceut Res, Dept Pharmacokinet & Drug Metab, Ann Arbor, MI 48105 USA
关键词
D O I
10.1021/jm980398y
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
Screening of a compound library led to the identification of 2-amino-6-(2,6-dichlorophenyl)-8-methylpyrido[2,3-d]pyrimidine (1) as a inhibitor of the platelet-derived growth factor receptor (PDGFr), fibroblast growth factor receptor (FGFr), and c-src tyrosine kinases (TKs). Replacement of the primary amino group at C-2 of 1 with a 4-(N,N-diethylaminoethoxy)phenylamino group yielded 2a, which had greatly increased activity against all three TKs. In the present work, variation of the aromatic group at C-6 and of the alkyl group at N-8 of the pyrido[2,3-d]pyrimidine core provided several analogues that retained potency, including derivatives that were biased toward inhibition of the TK activity of PDGFr. Analogues of 2a with a 3-thiophene or an unsubstituted phenyl group at C-6 were the most potent inhibitors. Compound 54, which had IC50 values of 31, 88, and 31 nM against PDGFr, FGFr, and c-src TK activity, respectively, was active in a variety of PDGF-dependent cellular assays and blocked the in vivo growth of three PDGF-dependent tumor lines.
引用
收藏
页码:4365 / 4377
页数:13
相关论文
共 50 条
  • [41] Novel 2-amino-4-anilino-6-methyl-5-substituted pyrrolo[2,3-D]pyrimidines as potential receptor tyrosine kinase inhibitors.
    Gangjee, A
    Jain, H
    Ihnat, M
    Kamat, S
    ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 2003, 226 : U13 - U13
  • [42] Chronic allograft nephropathy is prevented by inhibition of platelet-derived growth factor receptor: Tyrosine kinase inhibitors as a potential therapy
    Savikko, J
    Taskinen, E
    von Willebrand, E
    TRANSPLANTATION, 2003, 75 (08) : 1147 - 1153
  • [43] Design, synthesis and evaluation of 2-amino-4-m-bromoanilino-6-arylmethyl-7H-pyrrolo[2,3-d]pyrimidines as tyrosine kinase inhibitors and antiangiogenic agents
    Gangjee, Aleem
    Zhao, Ying
    Raghavan, Sudhir
    Ihnat, Michael A.
    Disch, Bryan C.
    BIOORGANIC & MEDICINAL CHEMISTRY, 2010, 18 (14) : 5261 - 5273
  • [44] Prevention of cardiac allograft arteriosclerosis by protein-tyrosine kinase inhibitor selective for platelet-derived growth factor receptor
    Koskinen, P
    Sihvola, R
    Myllärniemi, M
    Häyry, P
    Buchdunger, E
    Lemström, K
    TRANSPLANTATION PROCEEDINGS, 1999, 31 (1-2) : 102 - 102
  • [45] Tyrosine kinase activity of purified recombinant cytoplasmic domain of platelet-derived growth factor β-receptor (β-PDGFR) and discovery of a novel inhibitor of receptor tyrosine kinases
    Zaman, GJR
    Vink, PMF
    van den Doelen, AA
    Veeneman, GH
    Theunissen, HJM
    BIOCHEMICAL PHARMACOLOGY, 1999, 57 (01) : 57 - 64
  • [46] SUPPRESSION OF PLATELET-DERIVED GROWTH-FACTOR RECEPTOR TYROSINE KINASE-ACTIVITY BY UNSATURATED FATTY-ACIDS
    TOMASKA, L
    RESNICK, RJ
    JOURNAL OF BIOLOGICAL CHEMISTRY, 1993, 268 (07) : 5317 - 5322
  • [47] Effects of the indolocarbazole 3744W on the tyrosine kinase activity of the cytoplasmic domain of the platelet-derived growth factor β-receptor
    Uings, IJ
    Spacey, GD
    Bonser, RW
    CELLULAR SIGNALLING, 1999, 11 (02) : 95 - 100
  • [48] Novel 2-amino-4-anilino substituted-7-arylmethyl pyrrolo[2,3-D]pyrimidines as receptor tyrosine kinase inhibitors and antiangiogenic agents.
    Gangjee, A
    Zaware, N
    Ihnat, M
    Green, D
    Miller, WT
    ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 2005, 229 : U127 - U127
  • [49] Evaluation of a series of naphthamides as potent, orally active vascular endothelial growth factor receptor-2 tyrosine kinase inhibitors
    Weiss, Matthew M.
    Harmange, Jean-Christophe
    Polverino, Anthony J.
    Bauer, David
    Berry, Loren
    Berry, Virginia
    Borg, George
    Bready, James
    Chen, Danlin
    Choquette, Deborah
    Coxon, Angela
    DeMelfi, Tom
    Doerr, Nicholas
    Estrada, Juan
    Flynn, Julie
    Graceffa, Russell F.
    Harriman, Shawn P.
    Kaufman, Stephen
    La, Daniel S.
    Long, Alexander
    Neervannan, Sesha
    Patel, Vinod F.
    Potashman, Michele
    Regal, Kelly
    Roveto, Phillip M.
    Schrag, Michael L.
    Starnes, Charlie
    Tasker, Andrew
    Teffera, Yohannes
    Whittington, Douglas A.
    Zanon, Roger
    JOURNAL OF MEDICINAL CHEMISTRY, 2008, 51 (06) : 1668 - 1680
  • [50] A novel pyrrolo[3, 2-d]pyrimidine derivative, as a vascular endothelial growth factor receptor and platelet-derived growth factor receptor tyrosine kinase inhibitor, shows potent antitumor activity by suppression of tumor angiogenesis
    Awazu, Yoshiko
    Mizutani, Akio
    Nagase, Yoshinori
    Iwata, Hidehisa
    Oguro, Yuya
    Miki, Hiroshi
    Imamura, Shinichi
    Hori, Akira
    CANCER SCIENCE, 2012, 103 (05) : 939 - 944